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ABSTRACT 
Prostate cancer is the most common type of non-skin malignancy diagnosed among men, 
but the disease etiology and risk factors remain inconclusive. Hepatitis C virus (HCV) 
infection’s prevalence is increasing in the US population. Studies have shown that the 
concentration of free serum testosterone, which may be directly associated with prostate 
cancer risk, was decreased among men with HCV infection. In order to evaluate the 
relationship between HCV infection and prostate cancer risk, we conducted a population-
based case-control study using the SEER-Medicare dataset.  
The study included 194,339 prostate cancer cases and 54,481 controls which were 
frequency-matched to the cases by age, race, and calendar period of selection. After 
adjusting for matching factors and potential confounders, including geographic region of 
SEER registry/area, HBV infection, HIV infection, hypertension, number of 
hospitalization, number of outpatient visits, number of physician visits, and PSA test 0-
0.99 years prior to index date, history of HCV infection was significantly associated with 
decreased risk of prostate cancer (OR 0.76, 95% CI: 0.63-0.93). In addition, with the 
controls as the reference group, we observed HCV infection to be associated with 
reduced prostate cancer risk within each prostate cancer stage category at diagnosis: 
localized (OR 0.86, 95% CI: 0.59-1.24), regional (OR 0.90, 95% CI: 0.43-1.89), distant 
(OR 0.56, 95% CI: 0.26-1.17), and unstaged (OR 0.62, 95% CI: 0.38-1.00). 
Our finding that HCV infection is associated with reduced prostate cancer risk may lead 
to a greater understanding of prostate cancer etiology. Future research will be needed to 
elucidate the underlying biological mechanism for this inverse association. 
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INTRODUCTION 
Prostate cancer is the most common type of non-skin malignancy diagnosed among men, 
and the American Cancer Society has projected that about 238,590 new cases of prostate 
cancer will be diagnosed in the United States during 2013. Despite the high disease 
burden and wide-scope of research on prostate cancer etiology, the established risk 
factors of prostate cancer only include older age, a positive family history, and African-
American race (Hoffman, 2011; Dunn et al. 2011; Johns 2003). Interestingly, certain 
conditions, including diabetes mellitus (Kasper et al. 2006; Bonovas et al. 2004) and 
Human Immunodeficiency Virus (HIV) infection (Patel et al. 2008), seem to be 
associated with decreased risk of prostate cancer.  
Prostate cancer is rarely diagnosed clinically among men less than 40 years of age. The 
serum prostate-specific antigen (PSA) test has been widely adopted as a screening test for 
prostate cancer since the late 1980s (Lin et al. 2008), but the efficacy of the test has been 
controversial, as it has not been demonstrated to decrease mortality but induce harms 
such as over-diagnosis and over-treatment (Chou et al. 2011). PSA test diagnosed 
prostate cancer is usually asymptomatic and localized, compared to clinically detected 
prostate cancer, which is more likely to be diagnosed with regional extension or 
metastases (Hoffman et al. 2005). In 2011, the U.S. Preventive Services Task Force 
(USPSTF) recommended against screening for prostate cancer among all American men, 
regardless of age, race/ethnicity, or family history, as the current evidence indicates that 
the benefits of the test do not outweigh the harms (Moyer, 2012). 
It is estimated that approximately 2% (5.2 million) of the U.S. population is infected with 
hepatitis C virus (HCV) (Chak et al. 2011). HCV infection is an established strong risk 
factor for development of subsequent liver cirrhosis (Perz et al. 2006), hepatocellular 
carcinoma (HCC) (El-Serag 2000; Amin et al. 2006), and other liver complications 
(Hoofnagle 1997). Emerging evidence has also suggested a carcinogenic role of HCV 
infection in other types of cancer, including: non-Hodgkin lymphoma (NHL) (Matsuo et 
al. 2004; Giordano et al. 2007), thyroid cancer (Antonelli et al. 2007; Montella et al. 
2003), pancreatic cancer (El-Serag et al. 2009), and intrahepatic cholangiocarcinoma 
(Yamamoto et al. 2004). HCV-induced chronic liver inflammation causes accumulation 
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of reactive oxygen intermediates, which creates a mutagenic environment that inhibits 
DNA repair and allows the mutated cells to proliferate (Colombo 2003). This has been 
suggested to increase the risk of HCC. The increased NHL risk seen after HCV infection 
may be due to HCV-induced immune disturbance and B-cell proliferation  (Negri et al. 
2004; Gasparotto et al. 2002). There is also evidence that HCV core protein promotes cell 
proliferation and inhibits apoptosis(Chen et al. 2005), as a possible mechanism of HCV 
carcinogenesis.  
Extrahepatic manifestations of chronic HCV infection have been reported to include 
altered seminal parameters and reduced spermatogenesis (Hofny et al. 2011). Compared 
to healthy controls, HCV infected men are observed to have reduced semen volume and 
sperm motility (Hofny et al. 2011), and significantly lower free serum testosterone 
concentration (Durazzo et al. 2006). The latter may be explained by increased excretion 
of sex hormone-binding globulin after HCV infection (Nguyen et al. 2005). Testosterone 
is an androgen essential for proper function of the prostate gland, and previous research 
has suggested that higher serum testosterone levels are associated with increased risk of 
developing prostate cancer (Parsons et al. 2005). Therefore, it is possible that HCV-
infected men may have diminished risk of prostate cancer because of the decreased 
concentration of circulating testosterone.  
To our knowledge, no published study has examined the relationship between HCV 
infection and prostate cancer risk. In order to fill this research gap, we have conducted a 
population-based case-control study using the Surveillance, Epidemiology and End 
Results (SEER)-Medicare linked database.  Besides assessment of the exposure variable, 
this database also provides information about several other variables, including 
demographic features, medical history, healthcare utilization, and PSA testing history. 
The availability of these variables allowed us to adjust for potential confounders and 
obtain a more accurate estimate of prostate cancer risk among HCV-infected patients. 
Our research may lead to a greater understanding of prostate cancer etiology. 
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METHODS 
SEER-Medicare dataset 
The SEER program is funded by National Cancer Institute, and it collects data on cancer 
incidence and survival from US cancer registries. Presently, SEER includes 17 cancer 
registries, which covers approximately 26% of the US population. Medicare is a federally 
funded program which provides health insurance for approximately 97% of people aged 
65 years or older in the US population, as well as individuals under age 65 who have end-
stage renal disease or medical disability. Medicare is composed of four parts, including 
inpatient hospitalization program (Part A), physician visits and outpatient service 
program (Part B), Medicare Advantage plan (Part C) where benefits are provided by 
private companies that contract with Medicare, and outpatient prescription drug benefit 
(Part D). 
The SEER-Medicare is a linked database that provides demographic and clinical 
information for all incident cancers in the SEER program, as well as claims data for the 
individuals that are covered under Medicare and living in SEER regions (Engels et al. 
2011). Medicare data are available for both the cancer cases identified in the SEER 
program, and a 5% random sample of the Medicare population from the same geographic 
regions. Medicare data includes claims information for inpatient and hospitalization 
service (since 1986), and physician and outpatient services (since 1991). The claims are 
coded using International Classification of Diseases (ICD-9) codes, and Current 
Procedures Terminology (CPT-4) codes.  
Study design and subject selection 
In order to examine the risk of prostate cancer among HCV-infected individuals, we 
conducted a population-based case-control study using the SEER-Medicare dataset. Since 
almost all American people enter the Medicare program once their age reaches the 
eligibility criteria, Medicare can be considered as a cohort of the US general population 
65 years of age or older.  
This study was part of a larger project in which we systematically identified 1,084,247 
first primary cancer cases of any type diagnosed during 1993-2005 and aged 66 or older 
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at the time of diagnosis. We excluded persons of age 65 to assure sufficient time for the 
ascertainment of exposure information. Individuals who were diagnosed with cancer 
before 1993 were also excluded, since the Medicare system does not have claims data for 
HCV infection prior to 1993. The cases were required to have at least 12 month non-
health maintenance organization (HMO), Part A, and Part B Medicare claims data prior 
to the diagnosis of first cancer, in order to assure completeness of data and sufficient time 
to evaluate HCV infection status before cancer diagnosis. Cases diagnosed on autopsy or 
by death certificates only were excluded. The date of diagnosis was assigned as the index 
date for the cases.  
A total of 100,000 controls were randomly selected from the 5% random sample of 
Medicare recipients. Controls were frequency matched to the all-cancer cases by calendar 
year of case diagnosis, age, sex, and race. We required that controls be alive, and with no 
SEER-reported cancer on or before July 1st in the calendar year of selection. The same 
control could be selected multiple times for cases in different calendar years, and could 
become a cancer case in the future. The index date of the controls was July 1st of the 
selection year. Like cases, we required controls to have at least 12 months of non-HMO, 
Part A, and Part B Medicare coverage prior to their index dates.  
To conduct the current study, we extracted all first prostate cancer cases (194,339) and all 
male controls (54,481) into a sub-dataset, and used this sub-dataset to investigate the 
association between HCV infection and prostate cancer risk. This study can be 
conceptualized as a nested-case control study in the cohort of the US Medicare elderly 
population. 
Ascertainment of HCV infection status and covariates 
HCV infection status for the selected cases and controls was determined using the 
Medicare claims data. Subjects with one or more inpatient, hospital-based outpatient, or 
physician claims for HCV infection (ICD 9 codes: 070.41, 070.44, 070.51, 070.54, 
070.70, 070.71, or V02.62) were classified as having HCV infection. It is possible that 
the cancer patients received more diagnostic tests, including laboratory tests for HCV, 
during the period preceding their diagnosis than did controls during the period preceding 
their index date. As a result, cases are more likely to detect their asymptomatic hepatitis 
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viral infection than controls. Therefore, we excluded the HCV infections diagnosed 
within the 12-month period before cancer diagnosis or index date for both cases and 
controls, so as to avoid information bias.  
We collected information regarding other pertinent medical conditions for each selected 
individual, using the Medicare claims data for inpatient, hospital-based outpatient, or 
physician care. These conditions include diabetes mellitus (ICD 9 code: 250.0x), hepatitis 
B virus infection (HBV, 070.2, 070.3), hypertension (401.x-405.x), and HIV infection 
(042-044). We ascertained patients’ numbers of hospitalizations, hospital-based 
outpatient visits, and physician visits between age 65 and their index date, since we 
believe the utilization pattern of healthcare service may be associated with the likelihood 
of being diagnosed with prostate cancer or HCV infection. We expect that patients with 
HCV infection or chronic medical conditions would receive more healthcare services, 
including PSA screening tests, which increases the likelihood of diagnosis of early-stage 
prostate cancer. For the patients who had screening-detected cancer, their PSA tests were 
most probably done within a short period prior to their cancer diagnosis. As a result, we 
also assessed whether each subject had received PSA test 0-0.99 years prior to the index 
date, in order to adjust for the potential confounding caused by PSA screening.  
Statistical analysis 
We computed descriptive statistics of demographic characteristics, medical conditions, 
and healthcare utilization, for both prostate cancer cases and controls. We assessed 
whether these covariates were significantly associated with the primary exposure variable 
and the cancer outcome.  
We conducted stratified analyses by each covariate and examined whether the odds ratio 
(OR) for prostate cancer comparing HCV-infected to uninfected subjects was 
heterogeneous across levels of the covariates. For the continuous variables of healthcare 
utilization, we divided the variables at the median among the controls, and created new 
binary variables that represent the number of people who have more or less than or equal 
to the median numbers of visits to healthcare facilities. If no heterogeneity was found 
with assessment of the Breslow-Day test p-value, we used the Mantel-Haenzsel summary 
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OR to represent the risk of prostate cancer after HCV infection for each stratified 
analysis. 
To compare prostate cancer risk between HCV-infected and non-infected subjects, we 
used an unconditional logistic regression model to compute ORs and 95% confidence 
intervals (95% CIs), with adjustment for the matching factors and other potential 
confounders. The covariates included in the model were age, race, calendar period of 
selection (1993-1995, 1996-2000, 2001-2005), geographic region of SEER registry/area, 
HBV infection, HIV infection, hypertension, number of hospitalizations, number of 
hospital-based outpatient visits, number of physician visits, and whether the individual 
had received a PSA test 0-0.99 years prior to the index date.  A body of research has 
suggested that HCV infection leads to elevated risk of developing diabetes mellitus (Noto 
et al. 2006), and that the latter is associated with decreased the risk of prostate cancer, as 
mentioned previously. We therefore excluded diabetes from our model, since it may be in 
the causal pathway between HCV infection and prostate cancer risk.  
We suspected that having a PSA test 0-0.99 years prior to the index date may also be an 
effect modifier of the association between HCV infection and prostate cancer risk, so we 
included an interaction term between our primary predictor, HCV infection, and our PSA 
test variable in the above unconditional logistic regression model. If this interaction term 
was found to be statistically significant, it would suggest that the effect of HCV infection 
on prostate cancer risk differs according to whether the patient has received a PSA test 0-
0.99 years prior to their index date. As a result we would also report stratum-specific ORs 
according to PSA test status. 
In order to explore the association between HCV infection and prostate cancer risk 
stratified by stage at diagnosis, cases were divided into four cancer-stage categories: 
localized (stage I and II by the TNM system), regional (stage III by the TNM system), 
distant (stage IV by the TNM system), and unstaged. Using polytomous logistic 
regression, we calculated ORs for HCV-infected versus HCV uninfected subjects for 
each cancer stage category compared to controls, and assessed whether the ORs were 
heterogeneous. The interaction term between HCV infection and the PSA test variable 
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was also included in the above polytomous logistic regression models, in order to detect 
effect modification from PSA screening. 
To adjust for the multiple selection of a control across calendar years, and the possibility 
that a control can become a case in the future, the variance of the ORs from all logistic 
regression models were adjusted (Engels et al. 2011). 
RESULTS 
The study included 194,339 men with the diagnosis of first primary prostate cancer, and 
54,481 male controls (Table 1). Because of the large sample size, even a slight numerical 
difference between cases and controls can be statistically significant, but not necessarily 
meaningful. The mean ages of cases and controls were similar, 74.73 ± 6.14 years and 
75.17 ± 6.68 years, respectively. More than 80% of the subjects were white in both 
groups, but there were relatively more black subjects in the control group than in the case 
group (10.58% versus 6.43%, respectively). Among the cancer cases, 46% of the subjects 
were selected during 2001-2005, and approximately 25% were selected during 1993-
1995 and 1996-2000, respectively. The distribution of calendar period of selection is 
slightly different in the control group. Overall, the cases and controls were fairly well-
matched on age, race, and calendar period of selection from numerical comparison, 
despite the statistically significant difference.  
Table 1. Characteristics of cancer cases and controlsa 
Characteristic 
Prostate cancer   
Yes (N = 194,339)b No (N = 54,481)b P 
HCV  0.0015* 
Yes 469 (0.2%) 174 (0.3%)  
no 193,870 (99.8%) 54,307 (99.7%)  
Age (years) 74.7 ± 6.1 75.2 ± 6.7 < 0.001** 
Race < 0.001* 
White 45,747 (84.1%) 161,001 (83.0%)  
Black 3,497 (6.4%) 20,524 (10.6%)  
Others 5,124 (9.4%) 12,442 (6.4%)  
Calendar-period of selection < 0.001* 
1993-1995 49,918 (25.7%) 11,048 (20.3%)  
1996-2000 54,370 (28.0%) 16,277 (29.9%)  
2001-2005 90,051 (46.3%) 27,156 (49.8%)  
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History of diabetes   < 0.001* 
Yes 29,729 (15.3%) 9,780 (18.0%)  
No 164,612 (84.7%) 44,701 (82.1%)  
History of HBV   0.0018* 
Yes 212 (0.1%) 88 (0.2%)  
No 194,127 (99.9%) 54,393 (99.8%)  
History of hypertension   < 0.001* 
Yes 80,769 (41.6%) 23,719 (43.5%)  
No 113,570 (58.4%) 30,762 (56.5%)  
History of HIV    0.3751* 
Yes 302 (0.2%) 94 (0.2%)  
no 194,037 (99.8%) 54,387 (99.8%)  
PSA test 0-0.99 years prior to the index date < 0.001* 
Yes 132,048 (68.0%) 19,341 (35.5%)  
no 62,291 (32.1%) 35,140 (64.5%)  
# of hospitalizations 1.5 ± 2.4 1.6 ± 2.8 < 0.001*** 
# of outpatient visit 11.7 ± 17.5 11.5 ± 19.7 < 0.001*** 
# of physician visit 98.2 ± 100.8 96.7 ± 112.2 < 0.001*** 
a Table values are mean ± SD for continuous variables and n (column %) for categorical variables. 
b Percentages may not sum to 100% due to rounding. 
* P-value for χ2 test. ** P-value for t-test. ***P-value for Non-parametric test. 
 
In our dataset, 469 (0.24%) cases and 174 (0.32%) controls had a history of HCV 
infection. These proportions are substantially lower than the estimated prevalence of 
HCV infection (1.6%) in the US general population (Armstrong et al. 2006), but 
consistent with the percentage reported by Anderson et al. (2008) using analogous SEER-
Medicare data. Approximately 18.0% of subjects in the control group had a history of 
diabetes, compared to 15.3% in the case group. Less than 0.2% of cases and controls, 
respectively, had a history of HBV infection; the proportion of subjects with HIV 
infection was equally small in both groups. Hypertension was diagnosed in 41.6% of 
cases, which was slightly lower than the percentage of controls with hypertension. In 
addition, 68.0% of cases received a PSA test 0-0.99 year prior to their index dates, 
compared to 35.5% of the controls. Among the cases, 83.0% of HCV-infected men 
received a PSA test 0-0.99 years prior to their index date, compared to 67.9% among the 
HCV un-infected men. 
On average, the prostate cancer cases and controls were hospitalized 1.5 and 1.6 times, 
respectively, between age of 65 and the year of selection. The mean numbers of 
outpatient visits and physician visits were similar between cases and controls (about 12 
outpatient visits and 97 physician visits).  
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Table 2. Characteristics of HCV infected and uninfected subjectsa 
 
Characteristic 
HCV infection   
Yes (N = 643)b No (N = 248,177)b p 
Age (years) 74.0 ± 5.2 74.8 ± 6.3 < 0.001** 
Race < 0.001* 
White 461 (71.8%) 206,287 (83.3%)   
Black 111 (17.3%) 23,910 (9.7%)  
Others 70 (10.9%) 17,496 (7.1%)  
Calendar-period of selection < 0.001* 
1993-1995 9 (1.4%) 60,957 (24.6%)  
1996-2000 110 (17.1%) 70,537 (28.4%)  
2001-2005 524 (81.5%) 116,683 (47.0%)  
Diabetes < 0.001* 
Yes 194 (30.2%) 39,313 (15.8%)  
No 449 (69.8%) 208,864 (84.2%)  
Hepatitis B < 0.001* 
Yes 55 (8.6%) 245 (0.1%)  
No 588 (91.5%) 247,932 (99.9%)  
Hypertension < 0.001* 
Yes 411 (63.9%) 104,077 (41.9%)  
No 232 (36.1%) 144,100 (58.1%)  
HIV  < 0.001* 
Yes 19 (3.0%) 377 (0.2%)  
no 624 (97.1%) 247,800 (99.9%)  
PSA test 0-0.99 years prior to the index date < 0.001* 
Yes 472 (73.4%) 150,917 (60.8%)  
no 171 (26.6%) 97,260 (39.2%)  
Num of hospitalizations 2.9 ± 4.4 1.5 ± 2.5 < 0.001*** 
Num of outpatient visit 26.1 ± 34.0 11.6 ± 18.0 < 0.001*** 
Num of physician visit 205.6 ± 199.7 97.6 ± 102.9 < 0.001*** 
a Table values are mean ± SD for continuous variables and n (column %) for categorical variables. 
b Percentages may not sum to 100% due to rounding. 
* P-value for χ2 test. ** P-value for t-test. ***P-value for Non-parametric test. 
 
Table 2 compares the characteristics of the HCV infected and uninfected subjects. Their 
mean ages were similar. Among the HCV-infected subjects, 71.8% were white and 
17.3% were black, compared to 83.3% and 9.7%, respectively, for the uninfected 
subjects. More than 80% of the HCV-infected subjects, but only 47.0% of the HCV-
uninfected subjects, were selected during 2001-2005. For every medical condition, 
including diabetes, hepatitis B infection, hypertension, and HIV infection, the proportion 
of subjects having the condition was significantly and substantially greater among HCV-
infected subjects than among uninfected subjects. On average, the numbers of 
hospitalizations, outpatient visits and physician visits were approximately two times 
higher among HCV-infected subjects than among uninfected ones. Of note, 73.4% of 
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HCV-infected subjects received a PSA test 0-0.99 years prior to their index date, 
compared to approximately 60% among the uninfected subjects.  
Table 3. Stratified analysis by categorical covariates 
 
  
HCV 
infection 
Prostate cancer Mantel-Haenzsel OR 
(95% CI) 
Breslow-Day 
test p-value Yes No 
Race 0.74 (0.62, 0.88) 0.7557 
White  
(N = 206,748) 
Yes 331 1300 
 
No 160,67 45,617 
Black  
(N = 24,021) 
Yes 93 18 
No 20,431 3,479 
Others 
(N = 17,566) 
Yes 44 26 
no 12,398 5,098 
Calendar-period of selection 0.81 (0.68, 0.96) 0.7399 
1993-1995 
(N = 60,966) 
Yes 7 2 
 
No 49,911 11,046 
1996-2000 
(N = 70,647) 
Yes 77 33 
No 54,293 16,244 
2001-2005 
(N = 117,207) 
Yes 385 139 
no 89,666 27,017 
Diabetes 0.78 (0.65, 0.92) 0.9530 
Yes 
(N = 209,313) 
Yes 136 58 
 
No 29,591 9,722 
No 
(N = 39,507) 
Yes 333 116 
no 164,279 44,585 
Hepatitis B 0.78 (0.65, 0.93) 0.4010 
Yes 
(N = 300) 
Yes 39 16 
 
No 173 72 
No 
(N = 248,520) 
Yes 430 158 
no 193,697 54,235 
Hypertension 0.77 (0.65, 0.91) 0.5084 
Yes 
(N = 104,488) 
Yes 301 110 
 
No 80,468 23,609 
No 
(N = 144,332) 
Yes 168 64 
no 113,402 30,698 
HIV  0.76 (0.64, 0.90) 0.6453 
Yes 
(N = 396) 
Yes 12 7 
 
No 290 87 
No 
(N = 248,424) 
Yes 457 167 
no 193,580 54,220 
PSA test 0-0.99 years prior to the index date 0.60 (0.50, 0.72) 0.0956 
Yes 
(N = 151,389) 
Yes 389 83 
 
No 131,659 19,258 
No 
(N = 97,431) 
Yes 80 91 
no 62,211 35,049 
# of hospitalizations (median = 0) 0.73 (0.62, 0.87) 0.1256 
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> median 
(N = 130,359) 
Yes 324 125 
 
No 103,256 26,654 
<= median 
(N = 118,461) 
Yes 145 49 
no 90,614 27,653 
# of outpatient visits (median = 5) 0.71 (0.60, 0.85) 0.0147 
> median 
(N = 127,598) 
Yes 356 141 
 
No 101,746 25,355 
<= median 
(N = 121,222) 
Yes 113 33 
no 92,124 28,952 
# of physician visits (median = 61) 0.72 (0.61, 0.86) 0.3000 
> median 
(N = 130,678) 
Yes 402 140 
 
No 103,098 27,038 
<= median 
(N = 118,142) 
Yes 67 34 
no 90,772 27,269 
 
We conducted stratified analyses by each covariate and examined whether the OR for 
prostate cancer comparing HCV-infected to uninfected subjects was heterogeneous 
across levels of the covariates. Except for number of outpatient visits, the association 
between HCV infection and prostate cancer risk was not statistically different across 
categories of any covariates (Table 3). Thus, it is reasonable to use the Mantel-Haenzsel 
summary OR to represent the risk of prostate cancer after HCV infection for each 
stratified analysis except for number of outpatient visits. For all stratified analyses, the 
Mantel-Haenszel summary ORs were within the range of 0.60-0.81 and statistically 
significant, indicating that the risk of developing prostate cancer was lower among the 
HCV-infected compared to HCV-uninfected subjects after controlling for each covariate.  
Table 4. Association between HCV infection and prostate cancer riska,b 
Prostate cancer Number Odds Ratio (95% CI) 
Cancer 194,339 0.76 (0.63, 0.93)b 
No cancer 54,481 1.00 
a. The reference group is HCV-uninfected subjects. 
b. Adjusted for age, race, calendar-period of selection, geographic region of SEER registry/selection, HBV infection, 
HIV infection, hypertension, number of hospitalization, number of outpatient visits, number of physician visits, and 
PSA test 0-0.99 year prior to index date. 
 
With adjustment for matching factors and potential confounders, the interaction term 
between HCV infection and PSA test was not statistically significant (p=0.58), indicating 
that PSA test was not an effect modifier of this association, therefore our final model did 
not include interaction term. In the adjusted analysis, history of HCV infection was 
significantly associated with decreased risk of prostate cancer (OR 0.76, 95% CI: 0.63-
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0.93) (Table 4). In other words, the risk of developing prostate cancer is suggested to 
decrease by approximately 25% after HCV infection. Including diabetes mellitus in the 
model did not alter the OR substantially, suggesting that minimal proportion of HCV 
infection’s protective effect for prostate cancer is attributed to diabetes.  
Table 5. Association between HCV infection and stage at diagnosis of prostate cancera,b 
Stage Number Odds Ratio (95% CI) 
Controls  54,481 1.00 
Localized 94,894 0.86 (0.59, 1.24) 
Regional 14,406 0.90 (0.43, 1.89) 
Distant 15,608 0.56 (0.26, 1.17) 
Unstaged 69,431 0.62 (0.38, 1.00) 
 
Localized 94,894 1.00 
Regional 14,406 1.09 (0.71, 1.68) 
Distant 15,608 0.64 (0.42, 0.99) 
Unstaged 69,431 0.72 (0.58, 0.90) 
a. The reference group is people without HCV infection. 
b. Adjusted for age, race, calendar period of selection, geographic region of SEER registry/selection, HBV infection, 
HIV infection, hypertension, number of hospitalization, number of outpatient visits, number of physician visits, and 
history of PSA test 0-0.99 year prior to index date. 
 
In the polytomous logistic regression model with the controls as the reference group, we 
observed HCV infection to be associated with reduced prostate cancer risk within each 
prostate cancer stage category at diagnosis: localized (OR 0.86, 95% CI: 0.59-1.24), 
regional (OR 0.90, 95% CI: 0.43-1.89), distant (OR 0.56, 95% CI: 0.26-1.17), and 
unstaged (OR 0.62, 95% CI: 0.38-1.00) (Table 5). The strongest association was 
observed for the most advanced stage of prostate cancer. However, none of these 
associations were statistically significant, possibly due to limited power. The ORs were 
not heterogeneous from each other (p=0.88). The interaction term between HCV 
infection and PSA test was found not statistically significant (p=0.26), suggesting no 
effect modification from screening. 
When restricting our analysis to only cancer cases with localized cases as the reference 
group, we observed a weak, non-significant positive association between HCV infection 
and regional prostate cancer (OR 1.09, 95% CI: 0.71-1.68), but a negative and significant 
association between HCV infection and distant prostate cancer (OR 0.64, 95% CI: 0.42-
0.99) (Table 5). Again, the ORs were not heterogeneous from each other (p=0.27), and 
the interaction terms between HCV infection and PSA test was not significant (p=0.31). 
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DISCUSSION 
In this population-based case-control study, we have discovered that HCV infection was 
associated with reduced prostate cancer risk, after adjusting for demographic features, 
relevant medical conditions, numbers of visits to healthcare facilities, and PSA test 
history 0-0.99 years prior to the index date. In addition, our results suggested that this 
negative association was stronger for late stage prostate cancer than for earlier stage 
prostate cancer.  
Acute HCV infection is rarely discovered in clinical practice, and patients usually carry 
the virus for several years until non-specific symptoms such as fatigue appear. Duzarro et 
al. (2006) and Hofny et al. (2011) both reported that HCV-infected patients showed 
significantly lower levels of free testosterone compared to healthy controls. Nguyen et al. 
(2006) found that free testosterone concentration was inversely correlated with the 
severity of liver disease, and the concentration of sex hormone-binding globulin (SHBG) 
was higher among patients with more severe liver conditions. Two possible biological 
mechanisms have been proposed to explain the observed low level of free testosterone 
after HCV infection. One theory is that HCV infection causes primary hypogonadism 
(Danoff et al. 2006), under which condition, the functionalities of testicles are 
compromised and thus less testosterone is produced. Secondly, the chronic inflammation 
at the liver after HCV infection elevates the level of estrogen production (Shimizu et al. 
2001; Martino et al. 2004), and more SHBG are produced through the metabolism of 
estrogen. With increased the availability of testosterone-binding sites on SHBG, the 
concentration of free testosterone circulating in the system is decreased. High 
testosterone level has been linked with increased prostate cancer risk (Parsons et al. 
2005). The resulting lower level of circulating testosterone level may provide a plausible 
biological explanation for the observed diminishing prostate cancer risk among HCV-
infected subjects in our study.  
In the meta-analysis published by Kasper et al. (2006), the authors observed a significant 
inverse association between diabetes mellitus and risk of prostate cancer (RR=0.84, 95% 
CI: 0.76-0.93). The underlying mechanism was suggested to involve decreased 
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concentration of two hormones: insulin and testosterone. Patel et al. (2008) reported that 
the incidence of prostate cancer was significantly lower among HIV-infected individuals 
than the general US population (SIR=0.6, 95% CI 0.4-0.8), and HIV infection is known 
to decreased androgen levels (Engels et al. 2008). These inverse associations suggest that 
decreased circulating testosterone level diminishes prostate cancer risk, as seen among 
the HCV-infected individuals. 
In a study investigating cancer risks among elderly people with end-stage renal disease 
(ESRD, Shebl et al. 2012), the authors discovered that ESRD was associated with 
reduced risk for prostate cancer (OR=0.42, 95%CI: 0.35-0.50) using the same SEER-
Medicare dataset. Shebl (2012) postulated that patients with ESRD in general have less 
life expectancy, and consequently are less likely to receive PSA screening. The authors 
attributed the observed lower risk to a low prevalence of PSA screening or decreased 
sensitivity of the PSA test among patients with ESRD, rather than biological modulation 
by ESDR.  
However, the current analysis of the association between HCV infection and prostate 
cancer risk yielded a different explanation. In the current study, 73.4% HCV-infected 
subjects received PSA test 0-0.99 year prior to their index date, compared to 
approximately 60% among the uninfected subjects. Since the prevalence of PSA 
screening among HCV-infected subjects was substantially higher than the prevalence in 
HCV-uninfected subjects, HCV-infected subjects should be more likely to be diagnosed 
with prostate cancer. However, we actually observed a significantly reduced risk of 
prostate cancer for patients with prior HCV infection (OR 0.76, 95%CI: 0.63-0.93), 
indicating that this association would be even stronger without the attenuation effect from 
screening. Thus, it is very likely that the decreased prostate cancer risk after HCV 
infection is mediated by a biological substance-mediated mechanism and is not an artifact 
caused by screening.  
Interestingly, HCV infection was found to be associated with reduced prostate cancer risk 
within each cancer stage category (localized, regional, distant, and unstaged) comparing 
to the controls, and the strongest protective effect was observed for the most advanced 
stage of prostate cancer. In addition, among prostate cancer cases, a history of HCV 
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infection was associated with significantly decreased risk of distant cancer compared 
with localized cancer (OR 0.64, 95% CI: 0.42-0.99), suggesting that prostate cancer 
patients with HCV infection were more likely to have non-advanced cancer than 
advanced cancer. However, such findings may have been due to residual confounding by 
PSA screening. First, 68.0% of cases received a PSA test 0-0.99 years prior to their index 
dates, compared to 35.5% of the controls; secondly, among the cases, 83.0% of HCV-
infected subjects received a PSA test versus 67.9% of the HCV un-infected subjects. 
Since PSA testing tends to diagnose asymptomatic cancers at an early stage, it is possible 
that more non-advanced cancers were diagnosed due to the higher prevalence of PSA 
screening among cases, and particularly, among HCV-infected cases. Thus, the HCV-
infected cases may have been more likely to be diagnosed with non-advanced cancers, 
but they may not truly enjoy a biological protective effect against advanced cancer. 
The credibility of these findings is supported by various features of our study. The large 
sample size of the study provided substantial statistical power to detect the association 
between HCV infection and prostate cancer risk, and it enabled us to obtain a precise OR 
estimate. We included all prostate cancers cases aged 66 and older in the SEER program 
diagnosed during 1993-2005 and controls of the same age and from the same geographic 
areas. Thus, our study subjects were highly representative of the US elderly population. 
In addition, for patients who had screening-detected cancer, they were most likely to have 
received their PSA test within a short period prior to their cancer diagnosis. Thus, 
adjustment for PSA test 0-0.99 years prior to the index dates in the multivariate model 
addressed the potential confounding caused by screening, and ensured the validity of the 
observed association between HCV infection and decreased prostate cancer risk.  
Some limitations of our study are worth noting. First, we used Medicare claims data to 
ascertain HCV infection status, which is likely to underestimate the prevalence of HCV 
infection, considering that people often live asymptomatically for decades after their 
initial acute infection with HCV; in addition, it is possible that some of the identified 
subjects with ICD-9 code for HCV infection are actually false positives, which would 
decrease the specificity of our method of identifying exposure status. These situations 
would jeopardize the validity of our point estimate if the prostate cancer cases and 
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controls exhibited systematically different likelihoods of detection of their HCV 
infection. Secondly, controls were frequency matched to the age, race and calendar year 
of selection distribution of cancer cases of all type; selection of prostate cancer cases and 
all male controls for the current study broke this matching. However, the prostate cancer 
cases and controls were very balanced on age and race, and reasonably balanced on 
calendar-period of selection (Table 1); furthermore we adjusted for these variables in the 
multivariate model to adjust for any residual confounding. Thirdly, some of the identified 
PSA test may be performed after prostate cancer was suspected due to signs or 
symptoms, in which case, the PSA tests were not used as screening tests but diagnostic 
tests. 
CONCLUSIONS 
 In conclusion, we conducted the first population-based case-control study to investigate 
the association between HCV infection and prostate cancer risk with a large sample size. 
We found that HCV infection was significantly associated with decreased risk of 
developing prostate cancer. This association is grounded by a plausible biological 
mechanism involving decreased concentration of circulating testosterone. More in-depth 
research is needed to verify the underlying mechanism for the inverse association 
between HCV infection and prostate cancer. Further exploration of the association 
between HCV infection and stage at diagnosis of prostate cancer, as well as the role of 
PSA screening in this association, will also help elucidate the biological basis for our 
novel finding. 
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